Johnson & Johnson vs Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) — how do they compare? Johnson & Johnson trades at $258.39 (market cap $599.12B), while Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) trades at $58.55 (market cap $11.58B). The key difference: Johnson & Johnson is far larger — about 51.7× Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value)'s market cap, and Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) pays the higher dividend (3.73%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) for 0 Days on average.
| JNJ | TX | |
|---|---|---|
Market Cap | $599.12B | $11.58B |
Volume | 16,640,951 | 456,367 |
Sector | Health | Basic Materials |
52-Week High | $278.43 | $58.99 |
52-Week Low | $186.00 | $35.26 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $627.40B | $11.90B |
Dividend Yield | 2.16% | 3.73% |
Signals from Pluang's Aura AI — not financial advice
JNJ trades at $253.91, down 3.72% on the day, amid a mixed technical and fundamental backdrop. The stock shows strong profitability with a 21.48% net income margin and 25.74% ROE, supported by three consecutive quarterly EPS beats. Analyst consensus is bullish with a $282.73 price target, though recent news highlights competitive pressures and patent cliff concerns. Cash flow trends indicate robust operations but elevated investing outflows.
The outlook remains positive given JNJ's diversified healthcare portfolio and innovation pipeline, but investors face risks from debt levels rising to 24.06% of assets and biosimilar competition. Near-term resistance lies at $265, with support at $257. Institutional sentiment favors growth in pharmaceuticals and medical technology, though macroeconomic and regulatory headwinds persist.
Ternium (TX) trades at $58.99, up 1.81% with strong Q2 2026 earnings beating estimates by 43%. The stock shows solid fundamentals with attractive valuation metrics including P/E of 16.39 and P/S of 0.72. Recent analyst upgrades to Strong Buy highlight improving sentiment as Mexico's steel recovery drives operational momentum and the $4B Pesqueria project promises future capacity growth.
The stock offers value with 7% dividend yield projections and 14.5% upside to $65.52 fair value. Key risks include steel price volatility and trade uncertainty, but declining CapEx should boost free cash flow above 15% yield. Analyst consensus at $57.17 with 50% Buy ratings supports cautious optimism for continued recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Ternium S.A. is a Luxembourg-headquartered steel producer operating an integrated production system, from mining through finished flat and long steel products. It runs 18 production plants and two mining operations across Argentina, Brazil, Colombia, Guatemala, Mexico, and US, serving the automotive, construction, appliance, and energy industries.
Read more on TX →